Esperion Therapeutics Inc (ESPR) Financier

Esperion Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The company is headquartered in Ann Arbor, Michigan and currently employs 294 full-time employees. The company went IPO on 2013-06-24. The company markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels who are at risk of cardiovascular disease and nasal spray, loop diuretic for the treatment of edema associated with congestive heart failure, and hepatic and renal disease. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. NEXLETOL is a first-in-class ACLY inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating LDL receptors. NEXLIZET contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and cholesterol absorption in the intestine. Its Enbumyst is the FDA-approved nasal spray loop diuretic.